Biomerica (BMRA) Cash & Equivalents (2010 - 2026)

Biomerica (BMRA) has 17 years of Cash & Equivalents data on file, last reported at $1.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 56.31% year-over-year to $1.3 million; the trailing twelve-month figure through Feb 2026 stood at $1.3 million (down 56.31% YoY), and the FY2025 full-year result was $3.1 million, down 26.67% from the prior year.
• Cash & Equivalents retreated to $1.3 million in Q1 2026, from $2.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $10.2 million in Q1 2022 to a low of $1.3 million in Q1 2026.
• A 5-year average of $4.9 million and a median of $4.2 million in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents surged 92.96% in 2022 and plunged 67.12% in 2023, its largest moves.
• Tracing BMRA's Cash & Equivalents over 5 years: stood at $5.1 million in 2022, then soared by 40.81% to $7.1 million in 2023, then plunged by 66.75% to $2.4 million in 2024, then climbed by 7.21% to $2.5 million in 2025, then sank by 47.46% to $1.3 million in 2026.
• Business Quant data shows BMRA's Cash & Equivalents at $1.3 million in Q1 2026, $2.5 million in Q4 2025, and $3.1 million in Q3 2025.